HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Primary biliary cholangitis — Clinical Guidelines

Overview

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by chronic inflammation and destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and potentially cirrhosis 6 10.

Diagnosis

Key Diagnostic Criteria: Elevated alkaline phosphatase, antimitochondrial antibodies (AMA), and characteristic histological features of nonsuppurative destructive cholangitis 8 10.

Recommended Tests: Liver function tests, AMA, and liver biopsy for definitive diagnosis 8 10.

Grading Systems: Use of staging and grading systems based on histological findings, including newer systems that incorporate necroinflammatory activity 11 13.

Management

First-Line Treatment: Ursodeoxycholic acid (UDCA) at standard doses (typically 13-15 mg/kg/day) to improve biochemical markers and delay disease progression 10 12.

Adjunctive Treatments:

- Obeticholic acid (OCA): For patients with incomplete response to UDCA, with caution due to potential adverse effects 2 3 4. - Fibrates: Emerging evidence suggests potential benefit in patients with inadequate response to UDCA 7.

Monitoring: Regular biochemical markers (ALP, bilirubin, AST, ALT) and imaging to assess disease progression 8 12.

Special Populations

Elderly: PBC can present asymptomatically in elderly patients with normal liver tests; careful monitoring is essential 14 21.

Comorbidities: No specific guidelines provided in abstracts; management should consider overlapping symptoms and complications 10.

Key Recommendations

Initiate ursodeoxycholic acid (UDCA) as first-line therapy for all patients with confirmed PBC to delay disease progression (Evidence: Strong 10 12).

Consider obeticholic acid (OCA) for patients with inadequate response to UDCA, weighing benefits against potential adverse effects (Evidence: Moderate 2 3).

Regularly monitor biochemical markers and liver function to assess treatment efficacy and disease progression (Evidence: Moderate 8 12).

Liver biopsy remains crucial for definitive diagnosis and staging, especially in early disease stages (Evidence: Moderate 8 11).

Be vigilant for PBC in elderly patients, as it can present without typical symptoms or abnormal liver tests (Evidence: Weak 14 21).

References

1 Tan JJ, Chung AH, Loo JH, Quek JWE, Sharma S, Singh CL et al.. Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026. link 2 Giannini EG, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G et al.. Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis. Liver international : official journal of the International Association for the Study of the Liver 2025. link 3 Hai L, Wu J, Pan X, Yin W, Wu Z. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid. Pharmacoepidemiology and drug safety 2025. link 4 He Q, Jiang M, Wang Y, Zheng T. Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database. British journal of clinical pharmacology 2025. link 5 Qian Q, Wu Y, Cui N, Li Y, Zhou Y, Li Y et al.. Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases. Journal of autoimmunity 2024. link 6 Houri I, Hirschfield GM. Primary Biliary Cholangitis: Pathophysiology. Clinics in liver disease 2024. link 7 Zhang H, Li S, Feng Y, Zhang Q, Xie B. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis. Clinical and experimental medicine 2023. link 8 Corpechot C, Heurgue A, Tanne F, Potier P, Hanslik B, Decraecker M et al.. Non-invasive diagnosis and follow-up of primary biliary cholangitis. Clinics and research in hepatology and gastroenterology 2022. link 9 Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y et al.. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of hepatology 2021. link 10 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S et al.. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018. link 11 Kakuda Y, Harada K, Sawada-Kitamura S, Ikeda H, Sato Y, Sasaki M et al.. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Human pathology 2013. link 12 Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver international : official journal of the International Association for the Study of the Liver 2012. link 13 Nakanuma Y, Harada K. The role of the pathologist in diagnosing and grading biliary diseases. Clinics and research in hepatology and gastroenterology 2011. link 14 Dash A, Kragel P. Primary biliary cirrhosis in an elderly man with normal liver tests. Southern medical journal 2009. link 15 Sinclair D, Spedding A, Young R. Can the laboratory affect the investigation and diagnosis of primary biliary cirrhosis?. Journal of clinical pathology 2006. link 16 Blachar A, Federle MP, Brancatelli G. Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. Radiology 2001. link 17 Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. European journal of gastroenterology & hepatology 1999. link 18 Sharma BC, Saraswat VA, Choudhuri G, Das A, Ghoshal UC, Pandey R. Primary biliary cirrhosis without pruritus--an Indian variant. Tropical gastroenterology : official journal of the Digestive Diseases Foundation 1996. link 19 Grønnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime data analysis 1996. link 20 Epstein O. Review: the treatment of primary biliary cirrhosis. Alimentary pharmacology & therapeutics 1988. link 21 Holt KM, Miyai K, Chojkier M. Asymptomatic primary biliary cirrhosis in an old man. Journal of clinical gastroenterology 1986. link 22 van den Oord JJ, Fevery J, de Groote J, Desmet VJ. Immunohistochemical characterization of inflammatory infiltrates in primary biliary cirrhosis. Liver 1984. link 23 Yabu K, Kiyosawa K, Akahane Y, Shimakura K, Nagata A, Furuta S. A case of asymptomatic primary biliary cirrhosis with an initial presenting feature of localized gastric varices. Gastroenterologia Japonica 1983. link

Primary biliary cholangitis